Consistent with our findings, Fu and Lin reported that inhibiting IL-6 and IL-8 signaling using novel drug combinations (e.g., bazedoxifene/reparixin, bazedoxifene/SCH527123) achieved more effective treatment of triple-negative breast cancer and pancreatic ductal adenocarcinoma [41]. Here, CXCL8 is linked to triple-negative breast carcinoma.